Innovative Therapeutics Apogenix specializes in developing immunotherapeutics targeting TNFSF-dependent pathways for cancer and viral infections, representing a prime opportunity to offer advanced drug discovery, clinical trial support, or specialized biologics manufacturing services.

Funding & Growth With recent funding of over 27 million dollars and a growing revenue stream, Apogenix is actively expanding its pipeline and clinical programs, making it a strategic partner for collaborations in biotech innovation and transaction facilitation.

Focus on COVID-19 The company’s efforts in COVID-19 therapeutics, including the Phase III study of asunercept, open opportunities for supply chain, clinical trial logistics, and regulatory consulting tailored to pandemic-related product development.

Strategic Partnerships Recent collaborations with R-Biopharm and similar relationships highlight Apogenix’s openness to diagnostic and biomarker co-development, presenting sales leads for diagnostic tools, companion tests, and platform technologies.

Target Markets Operating within the biotech research sector with a focus on cancer and infectious disease treatments, Apogenix offers multiple avenues for technology licensing, research collaborations, and contract manufacturing services to accelerate their pipeline progression.